跳至主要内容
临床试验/NCT05222607
NCT05222607终止不适用

LONG RUN: LONGitudinal Evaluation and Real-world Evidence of Uniquely Purified incobotulinumtoxinA (Xeomin) in Treatment Naïve Participants

Merz North America, Inc.1 个研究点 分布在 1 个国家目标入组 11 人开始时间: 2023年2月10日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
终止
入组人数
11
试验地点
1
主要终点
Assessment of FACE-Q Patient-Perceived Age Visual Analogue Scale mean change

研究概览

简要总结

This study is to collect long-term real-world evidence data from clinics in several countries in order to obtain an improved understanding of the safety and effectiveness of incobotulinumtoxinA in botulinum neurotoxin type A (BoNT-A) treatment naïve participants.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 years of age or older.
  • Planning treatment with incobotulinumtoxinA.

排除标准

  • Any contraindication to treatment with incobotulinumtoxinA or any other neurotoxins.
  • Currently pregnant, breastfeeding, or intending to become pregnant during study participation.
  • Known hypersensitivity to incobotulinumtoxinA or any of its formulation ingredients.
  • Any infection and/or inflammation at the planned injection points.
  • Previous treatment with any botulinum toxin products for any aesthetic or therapeutic indications.

研究组 & 干预措施

Facial treatment with incobotulinumtoxinA in treatment naïve participants

干预措施: IncobotulinumtoxinA (Drug)

结局指标

主要结局

Assessment of FACE-Q Patient-Perceived Age Visual Analogue Scale mean change

时间窗: Up to 3 years

Explore the effectiveness of the incobotulinumtoxinA injections in treatment naïve participants for facial cosmetic procedures during up to 3 years continuous treatment exposure, as measured by assessment of FACE-Q Patient-Perceived Age Visual Analogue Scale mean change from first treatment visit to the 4-to-6 weeks timepoint.

次要结局

  • Assessment of FACE-Q Satisfaction with Decision Scale mean change(Up to 3 years)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验